Michael Kelly, PhD, on Gene Therapy’s Continuing Path to Treating DMD
The chief scientific officer of CureDuchenne discussed challenges to tackle in the field.
Michael Kelly, PhD, on Potential of Nonviral Approaches to DMD Gene Therapy
The chief scientific officer of CureDuchenne discussed how nonviral approaches may address issues including gene size and redosability.
Michael Kelly, PhD, on Continuing Progress in Muscular Dystrophy in 2024
The chief scientific officer of CureDuchenne discussed research he is looking forward to seeing in 2024.
Michael Kelly, PhD, on Continuing Progress With Gene Therapy in Muscular Dystrophy
The chief scientific officer of CureDuchenne discussed progress in the field so far and upcoming milestones.